MedTrace Logo

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants

NCT06362642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-11-13

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of PC14586 pharmacokinetics when co administered with itraconazole in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

PC14586

First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

DRUG

Itraconazole

Antifungal treatment that is a potent inhibitor of CYP3A4.

Sponsors & Collaborators

  • PMV Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-28
Primary Completion
2024-10-22
Completion
2024-10-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06362642 on ClinicalTrials.gov